Morphological Characteristics and Allometric Relationships of Shoot in Two Undergrowth Plants: Polygonatum odoratum and Polygonatum multiflorum

The main purpose of this investigation was to describe the spatial arrangement of shoot tissues, as seen in transverse section, and allometric relationships in two contrasting species of Polygonatum i.e., Polygonatum odoratum which commonly grows in mixed pine-oak forest with shoots rectangular in shape, and Polygonatum multiflorum found in oak-hornbeam forest with cylindrical shoots. The mass and length of the aerial shoots of each individual plant were measured. The shoot regions of each plant were then categorized as basal (b), central (c) or apical (a). Transverse sections of these shoot regions were subsequently cut, and the following parameters were measured: (1) Diameter of shoots, (2) thickness of the outer and inner zones of parenchyma and (3) thickness of the sclerenchyma zone. Additional allometric relationships between the various measurements were computed and determined as Pearson’s correlation coefficients (r). Both species of Polygonatum differed significantly with respect to the length, diameter and thickness of the outer zone of parenchyma. Shoots of P. multiflorum were taller but narrower than those of P. odoratum, which had a significantly wider zone of outer parenchyma. Allometric relationships were stronger for P. multiflorum, and for both species, they were generally stronger in the basal part of the shoot. We conclude that in P. multiflorum, the strong correlation between the diameter and length of the shoot seems to be important to the growth in shaded environments

COVID-19 and autoimmune diseases of the nervous system — an update

Introduction. Due to a similar pathomechanism, COVID-19 infection may significantly affect the course of autoimmune diseases (AIDs). In our review, we aimed to assess the severity of SARS-CoV-2 infection, response to treatment, and the impact of COVID-19 infection on the course of the underlying disease in patients with neuroimmune diseases. State of the art. In the time of the COVID-19 pandemic, it was important to determine the influence of COVID-19 infection on the course of autoimmune diseases due to the weakened immune system and immunosuppressive therapies. Clinical implications. Many reports have indicated that in patients with AIDs, the existence of the disease is not associated with a worse prognosis in the course of the viral infection. Patients in advanced stages of the disease, elderly patients, and those with comorbidities are at risk of more frequent hospitalisations and higher mortality in the course of COVID-19. Moreover, some drugs used in AIDs have been tested for their efficacy in SARS-CoV-2 infection. Episodes of newly diagnosed myasthenia gravis, Guillain-Barré syndrome, acute disseminated encephalomyelitis (ADEM), and neuromyelitis optica spectrum disorder (NMOSD) secondary to COVID-19 or vaccination have also been reported. Vaccination against this pathogen is highly recommended in most patients with AIDs. Future directions. Despite many studies on the association between COVID-19 and neuroimmune diseases, more specific data is needed. The approach to patients with AIDs should be individual, since many issues remain unresolved despite the long-lasting pandemic

Dysregulation of microRNAs in triple-negative breast cancer

Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and poor prognosis. TNBC is usually diagnosed at a relatively young age and is characterized by high risk of developing metastases. Some epigenetic regulation of gene expression is associated with TNBC. Expression of microRNAs (miRNAs) can serve as a potential tool for identifying critical biomarkers in TNBC. The aim of our study is to examine expression of selected miRNAs in TNBC and to assess the relationship between miRNA expression and clinicopathological factors. Material and methods: Expression levels of 19 selected miRNAs were compared between cancerous and normal breast tissues by use of qPCR method. We have evaluated the relationship between the expression level of miRNAs and clinicopathological factors such as: age, tumor size and lymph node status. Results: We found that in TNBC tissues, when compared with normal breast tissues, the expression of miR-190a, miR- 136-5p and miR-126-5p was significantly reduced (p = 0.0041, p = 0.0007, p = 0.0007, respectively) whereas expression of miR-135b-5p and miR-182-5p was significantly increased (p = 0.0194, p = 0.0041, respectively). We found a linear trend for tumor size and expression of miR-126-5p (p = 0.0296) and miR-135b-5p (p = 0.0241). Conclusions: Our study confirms that miRNA expression profile is dysregulated in TNBC patients compared to healthy controls. MiR-190a, miR-136-5p, miR-126-5p, miR-135b-5p and miR-182-5p may be associated with development and progression of TNB

The applications of infrared thermography in surgical removal of retained teeth effects assessment

during filling cavities, laser treatment and inflammation of periodontal tissues. The biggest problem in thermal imaging was limiting access and rapid change of humidity when the mouth opens during measurements. However, nowadays thermal map of body surface is correlated with inflammatory state changing inner mouth. The aim of this study was to assess the suitability of thermal imaging to localize the inflammation and monitor treatment effects after surgical removal of third retained molar teeth. The cohort consisted of 27 patients with referral for the surgical extraction of the third retained molar. Thermal imaging of the sagittal face was performed before and after the procedure and on the first, fourth and seventh day after the extraction. Obtained thermal maps are correlated with the third molar teeth inflammation location. Moreover, the changes of temperature in the area of both the tooth and the cheek correspond to the mechanisms of wound healing described in the literature. Obtained results were not only qualitative but also quantitative what was confirmed by statistically significant difference. It seems that thermal imaging, which is a noninvasive method, can be used to monitor treatment processes after surgical procedures, as well as on the location of inflammation

May thermal imaging be useful in the assessment of dentalanaesthesia? : preliminary study

The main goal of this study was to find out if thermal imaging may be useful in the evaluation of two types of anaesthetic injections-with and without a vasoconstrictor. There were 20 patients (13 women and 7 men) involved in the study. The group was divided into two subgroups. Patients from the first subgroup received infiltration anaesthesia (so-called: IA) of lidocaine (2 mL) and the second group included patients, who received infiltration anaesthesia (so-called: IAN) of lidocaine with 2% noradrenaline (2 mL). The obtained results showed a significant increase in the average temperature 10 min after the injection. In the IA group, the temperature increase was nearly 1.0 °C what was 0.3 °C higher than in the IAN group. Moreover, temperature changes showed a wide plateau between 10 and 25 min after anesthesia administration. The effect of temperature rise was also observed on the contralateral cheek where there was no intervention renders by a contralateral reflex

Sense of happiness in Polish patients with multiple sclerosis

Introduction. Happiness is crucial to patient well-being and their acceptance of their disease. The aim of this study was to assess the sense of happiness in persons with multiple sclerosis (PwMS), compare it to the level of happiness in patients with other neurological conditions, and determine which factors affect the sense of happiness in PwMS. Material and methods. Five hundred and eighty-nine PwMS and 145 control subjects (post-stroke patients with chronic pain syndromes and neuropathies) were included in the study. Due to the differences between the groups in terms of demographic variables, an adjusted group of PwMS (n = 145) was selected from the entire group of PwMS. All patients were assessed using the Oxford Happiness Questionnaire (OHQ), the Satisfaction with Life Scale (SLS), and the Family APGAR Questionnaire. Based on regression analysis, the study examined which variables affected the level of happiness in the groups. Results. Analysis of the OHQ scores showed that PwMS had a lower sense of happiness compared to the control group in the overall score [113.21 (25–42) vs. 119.88 (25–49), respectively; p = 0.031] and the subscales (OHQ subscale 1 — 54.52 vs. 57.84, respectively; p = 0.027; subscale 2 — 35.61 vs. 37.67; respectively; p = 0.044). Based on linear regression analysis, life satisfaction (β = 0.40; p < 0.001), positive orientation (β = 0.32; p < 0.001), and primary education (β = 0.08; p = 0.009) were the most significant predictors of a higher level of happiness in PwMS. Similar results were found in the control group. Conclusions. The sense of happiness in PwMS was lower than in patients with other conditions. The most important factors influencing happiness included life satisfaction and positive orientation. Influencing these predictors should be the aim of psychological interventions, especially in patients with a reduced sense of happiness

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe

The applications of thermal imaging in dental implant – pilot study

Termografia z roku na rok staje się coraz bardziej popularnym narzędziem diagnostycznym w medycynie i biologii. Poprzez analizę obrazów termicznych ciała możliwa jest ocena metabolizmu tkanek podpowierzchniowych. Pozwala to na lokalizację występowania stanów zapalnych oraz weryfikację procesów gojenia się tkanek poddanych zabiegom na podstawie zmian temperatury. Celem niniejszej pracy była próba zastosowania obrazowania termicznego w ocenie stanu zapalnego wywołanego założeniem śruby gojącej w trakcie zabiegu implantacji zęba. Obrazowanie termiczne wykonano przed i po zabiegu oraz w 2 i 12 dobie po zabiegu, oceniając zmiany temperatury w obszarze zabiegu (tzw. obszar zęba), w obszarze policzka po stronie zabiegu (tzw. obszar policzka) oraz w obszarze policzka zdrowego (tj. obszar kontrolny). Badania przeprowadzono na grupie 6 pacjentów, a otrzymane wyniki wskazują na wystąpienie stanu zapalnego po zabiegu, co wydaje się być efektem spodziewanym ze względu na procedury wiercenia i wkręcania śruby. Podwyższona temperatura w 2 dobie po zabiegu wskazuje na utrzymywanie się stanu zapalnego, a jej wyraźny spadek obserwowany jest w 12 dobie, co wskazuje na zakończenie fazy regeneracji i gojenia się tkanek. Wstępne pomiary mogą wskazywać na przydatność metody obrazowania termicznego w implantacji zębów.From year to year thermal imaging is becoming more and more popular diagnostic tool in medicine and biology. The metabolism of subsurface tissues is possible due to the thermal images analysis. Moreover, the inflammation location and tissue healing processes may be verified based on the temperature changes. The aim of study was to try to use thermal imaging in the inflammation assessment, which was caused by healing abutment of a dental implant location. Thermal imaging was done before and after treatment and in 2nd and 12th day after procedure. The assessment of temperature changes was done in procedure location ROI (so-called the tooth area), the cheek on the side of procedure ROI (so-called the cheek area) and the health cheek ROI (so-called the control side). The study included six patients, and the results indicate that inflammation appeared directly after the procedure. In fact, this was expected due to drilling and placing the healing abutment of a dental implant. The increased temperature in 2nd day after procedure may suggest that inflammation is maintained till 12th day, when the healing processes are ending. The preliminary results may indicate the usefulness of thermal imaging in dental implants monitoring

Multiple sclerosis immunomodulatory therapies tested for effectiveness in COVID-19

Introduction: The global pandemic of COVID-19 began in Wuhan, China in December 2019. Research into effective therapies has been conducted worldwide. Currently, there is no antiviral treatment and many patients develop a severe course of the disease, including severe respiratory failure. Due to similar pathomechanisms of inflammation in multiple sclerosis (MS) and COVID-19, immunomodulatory drugs that are registered for the treatment of MS are under study in the SARS-CoV-2 infection in clinical trials.Materials and methods: Using clinicaltrials.gov, we found information related to ongoing clinical studies on potential drugsfor COVID-19 which are also used in MS therapy. The outcomes of several trials were published on pubmed.ncbi.nlm.nih.gov.Results: There were 18 clinical trials evaluating the effectiveness and safety of interferon-β, fingolimod, or leflunomide inCOVID-19. Some trial outcomes available at pubmed.ncbi.nlm.nih.gov suggested an association of these drug treatments with improvements in signs and symptoms, and the disease course.Conclusion: The administration of immunomodulatory drugs in COVID-19 may result in potential beneficial effects probablyassociated with their anti-inflammatory and antiviral properties. Further research is warranted to confirm the long-term effects of immunomodulatory therapies in patients with COVID-19

The Comparison of the Selected Parameters of Brain Injury and Interleukins in the CSF in Patients Diagnosed De Novo with RRMS Compared to the Control Group

Background: Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system (CNS). Due to the different phenotypes of the disease and non-specific symptoms of MS, there is a great need for a validated panel of biomarkers to facilitate the diagnosis, predict disease progression, and evaluate treatment outcomes. Methods: We determined the levels of the parameters of brain injury (NF-H, GPAF, S100B, and UCHL1) and the selected cytokines in the cerebrospinal fluid (CSF) in 101 patients diagnosed de novo with RRMS and 75 healthy controls. All determinations were made using the Bio-Plex method. Results: We found higher levels of NF-H and GFAP in the relapsing-remitting multiple sclerosis (RRMS) group compared to the controls. The concentrations of both molecules were significantly increased in patients with Gd+ lesions on brain MRI. The level of S100B did not differ significantly between the groups. UCHL1 concentrations were higher in the control group. We found some correlations between the selected cytokines, the levels of the parameters of brain injury, and the time from the first symptoms to the diagnosis of MS. Conclusions: The role of the above molecules in MS is promising. However, further research is warranted to define their precise functions